IOVANCE BIOTHERAPEUTICS UK SP LTD
Get an alert when IOVANCE BIOTHERAPEUTICS UK SP LTD files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-06-14 (in 1mo)
Last made up 2025-05-31
Watchouts
None on the register
Cash
£6M
Latest balance sheet
Net assets
£115M
Equity attributable
Employees
4
Average over period
Profit before tax
£2M
Period ending 2024-12-31
Name history
Renamed 1 time since incorporation
- IOVANCE BIOTHERAPEUTICS UK SP LTD 2023-11-21 → present
- CLINIGEN SP LIMITED 2013-06-27 → 2023-11-21
Net assets
2-year trend · vs Consumer Discretionary median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £27,118,000 | £25,286,000 | |
| Operating profit | -£225,000 | £2,377,000 | |
| Profit before tax | -£221,000 | £2,433,000 | |
| Net profit | -£221,000 | £3,390,000 | |
| Cash | £799,000 | £6,179,000 | |
| Total assets less current liabilities | £111,436,000 | £115,043,000 | |
| Net assets | £111,436,000 | £115,043,000 | |
| Equity | £111,436,000 | £115,043,000 | |
| Average employees | 3 | 4 | |
| Wages | £194,000 | £321,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | -0.8% | 9.4% | |
| Net margin | -0.8% | 13.4% | |
| Return on capital employed | -0.2% | 2.1% | |
| Current ratio | 0.75x | 1.59x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors have reviewed budgets and other financial information and have concluded there is a reasonable expectation that the company has adequate financial resources to continue to operate existence and meet its liabilities as they fall due for a period of 12 months from the date of approval of the financial statements. In making such assessment, the directors have considered reasonably possible downside sensitivities, including the potential legislative risk of approving commercial sale of Amtagvi® in UK. Taking account of the relevant business risks, the directors believe that the company is well placed to continue to manage its business successfully. Accordingly, the directors continue to adopt the going concern basis in preparing the annual report and financial statements.”
Significant events
- “On 18 May 2023 the company was acquired by Iovance Biotherapeutics UK Limited and changed its name to Iovance Biotherapeutics UK SP Limited in November 2023.”
- “The company owns the worldwide rights to Proleukin® (aldesleukin) as well as the manufacturing, supply, and commercialisation income generated from such rights and associated operations.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 11 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| ROCHE, Corleen Marie | Director | 2025-08-06 | Oct 1965 | American |
| VOGT, Frederick | Director | 2023-05-18 | Aug 1973 | American |
Show 11 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| ABELL, Martin James | Secretary | 2017-03-02 | 2017-07-13 |
| HADDLETON, James Sidney | Secretary | 2015-11-02 | 2017-03-02 |
| MILLER, Amanda | Secretary | 2017-07-13 | 2023-01-16 |
| SIBSON, Robin Andrew John | Secretary | 2013-06-27 | 2015-11-02 |
| ABELL, Martin James | Director | 2015-12-01 | 2019-03-19 |
| BELLEMIN, Jean-Marc | Director | 2023-05-18 | 2025-06-30 |
| CHILTON, Shaun Edward | Director | 2014-04-01 | 2022-10-14 |
| GEORGE, Peter Lutz | Director | 2013-06-27 | 2016-11-11 |
| KEHER, Nicholas Patrick | Director | 2019-03-19 | 2021-08-24 |
| PALING, Richard John | Director | 2021-08-24 | 2023-05-18 |
| SIBSON, Robin Andrew John | Director | 2013-06-27 | 2015-12-01 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Iovance Biotherapeutics Uk Ltd | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2023-05-18 | Active |
| Clinigen Holdings Limited | Corporate entity | Shares 75–100%, Voting 25–50%, Appoints directors | 2019-03-27 | Ceased 2023-05-18 |
| Clinigen Pharma Limited | Corporate entity | Shares 75–100%, Voting 25–50%, Appoints directors | 2017-06-28 | Ceased 2019-03-27 |
Filing timeline
Last 20 of 73 total filings
Material constitutional events — rename, articles re-file, resolution
- 2023-11-21 CERTNM Certificate change of name company PDF
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-10-21 | AA | accounts | Accounts with accounts type full | |
| 2025-09-08 | AP01 | officers | Appoint person director company with name date | |
| 2025-09-05 | TM01 | officers | Termination director company with name termination date | |
| 2025-06-13 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-03-18 | AA | accounts | Accounts with accounts type full | |
| 2024-06-12 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-11-21 | CERTNM | change-of-name | Certificate change of name company | |
| 2023-09-13 | AA01 | accounts | Change account reference date company current extended | |
| 2023-07-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-06-12 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2023-06-12 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2023-06-12 | AD01 | address | Change registered office address company with date old address new address | |
| 2023-05-30 | TM01 | officers | Termination director company with name termination date | |
| 2023-05-30 | AP01 | officers | Appoint person director company with name date | |
| 2023-05-30 | AP01 | officers | Appoint person director company with name date | |
| 2023-05-05 | AA | accounts | Accounts with accounts type audit exemption subsiduary | |
| 2023-05-05 | PARENT_ACC | accounts | Legacy | |
| 2023-05-05 | AGREEMENT2 | other | Legacy | |
| 2023-05-05 | GUARANTEE2 | other | Legacy | |
| 2023-05-02 | SH19 | capital | Capital statement capital company with date currency figure |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31